https://invivoscribe.com/now-available-mrd-solutions-for-b-and-t-cell-clonality-tracking/ 2019-09-23T22:05:58+00:00 https://invivoscribe.com/invivoscribe-to-exhibit-at-25th-eha-annual-congress/ 2020-05-27T18:11:58+00:00 https://invivoscribe.com/wp-content/uploads/2020/05/Invivoscribe-EHA25-Event-Post-Featured-Image-001.jpg https://invivoscribe.com/invivoscribe-to-participate-in-virtual-asco-2020/ 2020-05-27T18:13:43+00:00 https://invivoscribe.com/wp-content/uploads/2019/05/Invivoscribe-Events-ASCO-2019-FS-Desktop-Background-Image-001.jpg https://invivoscribe.com/validation-and-interpretation-of-igh-and-tcr-clonality-testing-by-ion-torrent-s5-ngs-for-diagnosis-and-disease-monitoring-in-b-and-t-cell-cancers/ 2021-02-11T19:51:54+00:00 https://invivoscribe.com/classification-of-intestinal-t%e2%80%90cell-receptor-repertoires-using-machine-learning-methods-can-identify-patients-with-coeliac-disease-regardless-of-dietary-gluten-status/ 2021-02-11T19:57:34+00:00 https://invivoscribe.com/comparison-of-next-generation-sequencing-ngs-and-next-generation-flow-ngf-for-minimal-residual-disease-mrd-assessment-in-multiple-myeloma/ 2021-02-11T20:05:42+00:00 https://invivoscribe.com/plasticity-of-the-human-igm-repertoire-in-response-to-long%e2%80%90term-spaceflight/ 2021-02-11T20:09:45+00:00 https://invivoscribe.com/immune-recovery-in-patients-with-mantle-cell-lymphoma-receiving-long-term-ibrutinib-and-venetoclax-combination-therapy/ 2021-02-11T20:11:02+00:00 https://invivoscribe.com/genetic-evolution-of-in-situ-follicular-neoplasia-to-aggressive-b-cell-lymphoma-of-germinal-center-subtype/ 2021-02-11T20:13:51+00:00 https://invivoscribe.com/baseline-vdj-clonotype-detection-using-a-targeted-sequencing-ngs-assay-allowing-for-subsequent-mrd-assessment/ 2021-02-11T20:26:38+00:00 https://invivoscribe.com/evaluation-of-the-polymerase-chain-reaction-based-t-cell-receptor-%ce%b2-clonality-test-in-the-diagnosis-of-early-mycosis-fungoides/ 2021-02-11T21:43:52+00:00 https://invivoscribe.com/evaluation-of-somatic-hypermutation-status-in-chronic-lymphocytic-leukemia-cll-in-the-era-of-next-generation-sequencing/ 2021-02-11T21:47:46+00:00 https://invivoscribe.com/upgraded-standardized-minimal-residual-disease-detection-by-next-generation-sequencing-in-multiple-myeloma/ 2021-02-11T21:50:38+00:00 https://invivoscribe.com/primary-non-hodgkin-lymphoma-of-the-tongue-base-the-clinicopathology-of-seven-cases-and-evaluation-of-hpv-and-ebv-status/ 2021-02-11T21:53:32+00:00 https://invivoscribe.com/quantitation-of-cmv-specific-t-cell-expansion-using-t-cell-receptor-beta-locus-deep-sequencing-to-identify-patients-at-risk-of-viral-complications/ 2021-02-11T21:56:18+00:00 https://invivoscribe.com/molecular-profiling-of-immunoglobulin-heavy-chain-gene-rearrangements-unveils-new-potential-prognostic-markers-for-multiple-myeloma-patients/ 2021-02-11T21:58:45+00:00 https://invivoscribe.com/monitoring-minimal-residual-disease-in-the-bone-marrow-using-next-generation-sequencing/ 2021-02-11T22:00:56+00:00 https://invivoscribe.com/plasma-cell-myeloma-residual-disease-quantitation-using-a-next-generation-sequencing-based-igh-clonal-rearrangement-assay-with-the-aid-of-a-spike-in-clonal-sequence/ 2021-02-11T23:36:10+00:00 https://invivoscribe.com/clonally-related-cd5-cll-sll-and-cd10-high-grade-b-cell-lymphoma-suggests-common-neoplastic-progenitor-with-branched-disease-evolution-with-therapeutic-implications/ 2021-02-11T23:40:44+00:00 https://invivoscribe.com/stability-and-uniqueness-of-clonal-immunoglobulin-cdr3-sequences-for-mrd-tracking-in-multiple-myeloma/ 2021-02-11T23:43:09+00:00 https://invivoscribe.com/establishment-of-immunoglobulin-heavy-igh-chain-clonality-testing-by-next-generation-sequencing-for-routine-characterization-of-b-cell-and-plasma-cell-neoplasms/ 2021-02-11T23:46:14+00:00 https://invivoscribe.com/a-next-generation-sequencing-based-assay-for-minimal-residual-disease-assessment-in-aml-patients-with-flt3-itd-mutations/ 2021-02-11T23:49:39+00:00 https://invivoscribe.com/simple-deep-sequencing-based-post-remission-mrd-surveillance-predicts-clinical-relapse-in-b-all/ 2021-02-11T23:54:51+00:00 https://invivoscribe.com/minimal-residual-disease-mrd-status-following-induction-chemo-immunotherapy-predicts-progression-free-survival-in-mantle-cell-lymphoma-mcl-calgb-50403-alliance/ 2021-02-12T00:14:15+00:00 https://invivoscribe.com/t-and-b-cell-clonal-expansion-in-ras-associated-lymphoproliferative-disease-rald-as-revealed-by-next-generation-sequencing/ 2021-02-12T00:17:56+00:00 https://invivoscribe.com/phenotypic-and-functional-characterization-of-t-cells-in-white-matter-lesions-of-multiple-sclerosis-patients/ 2021-02-12T00:57:59+00:00 https://invivoscribe.com/detection-of-immunoglobulin-heavy-chain-gene-clonality-by-next-generation-sequencing-for-minimal-residual-disease-monitoring-in-b-lymphoblastic-leukemia/ 2021-02-12T00:59:47+00:00 https://invivoscribe.com/molecular-pathology-diagnosis-of-diffuse-large-b-cell-lymphoma-using-biomed-2-clonal-gene-rearrangements/ 2021-02-12T01:03:26+00:00 https://invivoscribe.com/in-vitro-co-expression-of-human-amyloidogenic-immunoglobulin-light-and-heavy-chain-proteins-a-relevant-cell-based-model-of-al-amyloidosis/ 2021-02-12T01:06:38+00:00 https://invivoscribe.com/a-small-case-series-of-intravascular-large-b-cell-lymphoma-with-unexpected-findings-subset-of-cases-with-concomitant-extravascular-central-nervous-system-cns-involvement-mimicking-primary-cns-lymph/ 2021-02-12T01:10:12+00:00 https://invivoscribe.com/targeted-deep-sequencing-reveals-clinically-relevant-subclonal-ighv-rearrangements-in-chronic-lymphocytic-leukemia/ 2021-02-12T18:36:01+00:00 https://invivoscribe.com/the-evolution-of-clonality-testing-in-the-diagnosis-and-monitoring-of-hematological-malignancies/ 2021-02-12T20:42:59+00:00 https://invivoscribe.com/molecular-genetic-data-favoring-a-sequential-clonal-transformation-of-a-large-b-cell-lymphoma-into-an-anaplastic-large-t-cell-lymphoma-alk-negative/ 2021-02-12T20:48:04+00:00 https://invivoscribe.com/clinical-scale-rapid-autologous-bk-virus-specific-t-cell-line-generation-from-kidney-transplant-recipients-with-active-viremia-for-adoptive-immunotherapy/ 2021-02-12T21:23:31+00:00 https://invivoscribe.com/breast-implant-associated-anaplastic-large-cell-lymphoma-two-distinct-clinicopathological-variants-with-different-outcomes/ 2021-02-12T22:19:56+00:00 https://invivoscribe.com/discordant-lymphoma-consisting-of-mediastinal-large-b-cell-lymphoma-and-nodular-sclerosis-hodgkin-lymphoma-in-the-right-supraclavicular-lymph-nodes-a-case-report/ 2021-02-12T22:24:11+00:00 https://invivoscribe.com/mucosal-cd30-positive-t-cell-lymphoproliferative-disorder-arising-in-the-oral-cavity-following-dental-implants/ 2021-02-12T22:28:17+00:00 https://invivoscribe.com/immunoglobulin-transcript-sequence-and-somatic-hypermutation-computation-from-unselected-rna-seq-reads-in-chronic-lymphocytic-leukemia/ 2021-02-13T00:38:16+00:00 https://invivoscribe.com/deep-sequencing-reveals-clonal-evolution-patterns-and-mutation-events-associated-with-relapse-in-b-cell-lymphomas/ 2021-02-13T00:42:37+00:00 https://invivoscribe.com/immunoblastic-follicular-lymphoma-a-very-unusual-transformation-of-low-grade-follicular-lymphoma/ 2021-02-13T00:46:19+00:00 https://invivoscribe.com/pomalidomide-dexamethasone-and-daratumumab-in-relapsed-refractory-multiple-myeloma-after-lenalidomide-treatment/ 2021-02-15T19:48:14+00:00 https://invivoscribe.com/standardized-minimal-residual-disease-detection-by-next-generation-sequencing-in-multiple-myeloma/ 2021-02-15T20:01:10+00:00 https://invivoscribe.com/routine-evaluation-of-minimal-residual-disease-in-myeloma-using-next-generation-sequencing-clonality-testing/ 2021-02-17T18:10:07+00:00 https://invivoscribe.com/clonality-of-multiple-distinct-lymphoproliferative-disorders-occurring-within-individual-hiv-patients/ 2021-02-18T21:08:35+00:00 https://invivoscribe.com/hydroa-vacciniforme-like-lymphoma-a-chronic-ebv-lymphoproliferative-disorder-with-risk-to-develop-a-systemic-lymphoma/ 2021-02-18T21:10:55+00:00 https://invivoscribe.com/paediatric-and-adolescent-elevated-conjunctival-lesions-in-the-plical-area-lymphoma-or-reactive-lymphoid-hyperplasia/ 2021-02-18T21:14:44+00:00 https://invivoscribe.com/diagnostic-utility-of-a-clonality-test-for-lymphoproliferative-diseases-in-koreans-using-the-biomed-2-pcr-assay/ 2021-02-18T21:18:36+00:00 https://invivoscribe.com/dried-blood-spot-sampling-for-detection-of-monoclonal-immunoglobulin-gene-rearrangement/ 2021-02-18T21:22:32+00:00 https://invivoscribe.com/euroclonality-biomed-2-guidelines-for-interpretation-and-reporting-of-ig-tcr-clonality-testing-in-suspected-lymphoproliferations/ 2021-02-18T21:25:10+00:00 https://invivoscribe.com/a-practical-approach-to-diagnostic-ig-tcr-clonality-evaluation-in-clinical-pathology/ 2021-02-18T22:35:18+00:00 https://invivoscribe.com/multiple-clonal-ig-tcr-products-implications-for-interpretation-of-clonality-findings/ 2021-02-18T22:37:16+00:00 https://invivoscribe.com/molecular-diagnostics-of-hematologic-malignancies/ 2021-02-18T22:44:51+00:00 https://invivoscribe.com/imgt-geneinfo-t-cell-receptor-gamma-trg-and-delta-trd-genes-in-database-give-access-to-all-tr-potential-vdj-recombinations/ 2021-02-18T22:47:08+00:00 https://invivoscribe.com/imgt-junctionanalysis-the-first-tool-for-the-analysis-of-the-immunoglobulin-and-t-cell-receptor-complex-v-j-and-v-d-j-junctions/ 2021-02-18T22:53:47+00:00 https://invivoscribe.com/invivoscribe-submits-leukostrat-cdx-flt3-mutation-assay-to-nmpa-in-china-and-expands-company-adding-laboratory-in-shanghai-to-provide-comprehensive-support-for-partners/ 2021-02-26T19:10:05+00:00 https://invivoscribe.com/japans-mhlw-approves-invivoscribes-leukostrat-cdx-flt3-mutation-assay-as-the-cdx-for-daiichi-sankyos-quizartinib-for-treatment-of-relapsed-refractory-flt3-itd-aml-expands/ 2021-02-26T19:10:37+00:00 https://invivoscribe.com/invivoscribe-expanding-clinical-laboratory-network-space-and-testing-capabilities-in-san-diego-germany-japan-and-china-offering-comprehensive-standardized-testing-for-all-hematologic-malignancies/ 2021-02-26T19:10:45+00:00 https://invivoscribe.com/invivoscribe-to-present-at-biotech-showcase-2019-in-san-francisco/ 2021-02-26T19:10:54+00:00 https://invivoscribe.com/us-fda-approves-invivoscribe-leukostrat-cdx-flt3-mutation-assay-as-cdx-and-astellas-drug-xospata-gilteritinib-fumarate-for-treatment-of-aml-patients-in-the-us/ 2021-02-26T19:11:02+00:00 https://invivoscribe.com/invivoscribe-submits-the-leukostrat-cdx-flt3-mutation-assay-to-support-daiichi-sankyo-submission-for-quizartinib-in-japan/ 2021-02-26T19:11:48+00:00 https://invivoscribe.com/invivoscribe-announces-a-regional-center-of-excellence-reference-laboratory-in-beirut-to-offer-specialized-gene-panels/ 2021-02-26T19:12:15+00:00 https://invivoscribe.com/invivoscribe-submits-pre-market-approval-application-in-japan-and-panel-track-supplement-in-the-us-to-screen-acute-myeloid-leukemia-aml-patients-for-flt3-mutations/ 2021-02-26T19:12:23+00:00 https://invivoscribe.com/invivoscribe-releases-lymphotrack-trb-assay-on-miseq-and-lymphotrack-minimal-residual-disease-mrd-software/ 2021-02-26T19:12:40+00:00 https://invivoscribe.com/invivoscribe-releases-leukostrat-cdx-flt3-mutation-assay-as-ce-marked-ivd-assay-kit/ 2021-02-26T19:12:46+00:00 https://invivoscribe.com/fda-approves-new-combination-treatment-for-acute-myeloid-leukemia/ 2021-02-26T19:12:55+00:00 https://invivoscribe.com/invivoscribe-receives-fda-approval-for-the-leukostrat-cdx-flt3-mutation-assay-companion-diagnostic-test-for-the-selection-of-patients-for-rydapt-and-is-the-first-companion-diagnostic/ 2021-02-26T19:13:02+00:00 https://invivoscribe.com/invivoscribe-expands-business-into-solid-tumors-with-assays-and-services-to-identify-and-monitor-car-t-and-tcr-immuno-therapies/ 2021-02-26T19:13:49+00:00 https://invivoscribe.com/invivoscribe-expands-ion-pgm-ngs-platform-menu-releases-additional-ce-ivd-clonality-kits-with-bioinformatics-software-and-ruo-kits-with-mrd-software/ 2021-02-26T19:13:58+00:00 https://invivoscribe.com/invivoscribe-announces-long-term-collaboration-agreement-with-illumina-and-plans-release-of-ngs-based-ivd-assay-kits/ 2021-02-26T19:14:04+00:00 https://invivoscribe.com/invivoscribe-expands-long-term-collaboration-agreement-to-release-flt3-mutation-and-clonality-assay-kits/ 2021-02-26T19:14:11+00:00 https://invivoscribe.com/novartis-drug-pkc412-midostaurin-granted-fda-priority-review-for-newly-diagnosed-flt3-mutated-aml-and-advanced-systemic-mastocytosis/ 2021-02-26T19:14:23+00:00 https://invivoscribe.com/ion-torrent-developers-alliance-program-designed-to-speed-targeted-ngs-assay-development/ 2021-02-26T19:14:30+00:00 https://invivoscribe.com/german-supreme-court-upholds-and-strengthens-invivoscribe-flt3-patent-position/ 2021-02-26T19:14:37+00:00 https://invivoscribe.com/invivoscribe-expanding-clinical-laboratory-network-space-and-testing-capabilities-in-san-diego-germany-japan-and-china-offering-comprehensive-standardized-testing-for-all-hematologic-malignancies-2-2/ 2021-02-26T19:14:49+00:00 https://invivoscribe.com/invivoscribe-announces-long-term-collaboration-to-develop-immuno-oncology-tests-with-thermo-fisher-scientific/ 2021-02-26T19:15:19+00:00 https://invivoscribe.com/novartis-drug-pkc412-midostaurin-improves-overall-survival-by-23-in-global-phase-iii-study-of-aml-patients-with-flt3-mutations/ 2021-02-26T19:16:48+00:00 https://invivoscribe.com/end-of-treatment-peripheral-blood-tcr-evaluation-for-minimal-residual-disease-evaluation-in-peripheral-t-cell-lymphomas/ 2021-03-03T23:40:33+00:00 https://invivoscribe.com/wp-content/uploads/2021/03/End-of-Treatment-Peripheral-Blood-TCR-Evaluation-for-Minimal-Residual-Disease-Evaluation-in-Peripheral-T-cell-Lymphomas-Poster-Image.jpg https://invivoscribe.com/wp-content/uploads/2021/03/End-of-Treatment-Peripheral-Blood-TCR-Evaluation-for-Minimal-Residual-Disease-Evaluation-in-Peripheral-T-cell-Lymphomas-Poster-Image.jpg https://invivoscribe.com/ampa-next-generation-sequencing-based-analysis-of-clonality-across-39-subjects-treated-for-lymphoproliferative-disorders-reveals-matching-clones-in-the-diverse-igh-locus/ 2021-03-03T23:53:52+00:00 https://invivoscribe.com/wp-content/uploads/2021/03/A-Next-Generation-Sequencing-Based-Analysis-of-Clonality-across-39-Subjects-Treated-for-Lymphoproliferative-Disorders-Reveals-Matching-Clones-in-the-Diverse-IGH-Locus.jpg https://invivoscribe.com/wp-content/uploads/2021/03/A-Next-Generation-Sequencing-Based-Analysis-of-Clonality-across-39-Subjects-Treated-for-Lymphoproliferative-Disorders-Reveals-Matching-Clones-in-the-Diverse-IGH-Locus.jpg https://invivoscribe.com/trg-clonality-interrogation-by-ce-and-ngs-bridging-the-gap-between-classical-and-leading-edge-technologies/ 2021-03-03T23:55:00+00:00 https://invivoscribe.com/wp-content/uploads/2021/03/TRG-Clonality-Interrogation-by-CE-and-NGS-Bridging-the-Gap-Between-Classical-and-Leading-Edge-Technologies-Poster-Image.jpg https://invivoscribe.com/wp-content/uploads/2021/03/TRG-Clonality-Interrogation-by-CE-and-NGS-Bridging-the-Gap-Between-Classical-and-Leading-Edge-Technologies-Poster-Image.jpg https://invivoscribe.com/comparing-dna-extraction-methods-for-the-lymphotrack-ivd-trg-assay/ 2021-03-05T20:38:02+00:00 https://invivoscribe.com/wp-content/uploads/2021/03/Comparing-DNA-Extraction-Methods-for-the-LymphoTrack-IVD-TRG-Assay-Poster-Image.jpg https://invivoscribe.com/wp-content/uploads/2021/03/Comparing-DNA-Extraction-Methods-for-the-LymphoTrack-IVD-TRG-Assay-Poster-Image.jpg https://invivoscribe.com/evaluation-of-an-alternative-fragmentation-method-in-high-throughput-ngs-sample-testing-of-minimal-residual-disease-in-hematological-malignancies/ 2021-03-05T20:44:34+00:00 https://invivoscribe.com/wp-content/uploads/2021/03/Evaluation-of-An-Alternative-Fragmentation-Method-in-High-Throughput-NGS-Sample-Testing-of-Minimal-Residual-Disease-in-Hematological-Malignancies-Poster-Image.jpg https://invivoscribe.com/wp-content/uploads/2021/03/Evaluation-of-An-Alternative-Fragmentation-Method-in-High-Throughput-NGS-Sample-Testing-of-Minimal-Residual-Disease-in-Hematological-Malignancies-Poster-Image.jpg https://invivoscribe.com/validation-of-an-ngs-based-assay-for-monitoring-flt3-itd-and-tkd-variants-in-aml-subjects/ 2021-03-05T20:49:11+00:00 https://invivoscribe.com/wp-content/uploads/2021/03/Validation-of-an-NGS-based-assay-for-monitoring-FLT3-ITD-and-TKD-variants-in-AML-subjects-Poster-Image.jpg https://invivoscribe.com/wp-content/uploads/2021/03/Validation-of-an-NGS-based-assay-for-monitoring-FLT3-ITD-and-TKD-variants-in-AML-subjects-Poster-Image.jpg https://invivoscribe.com/validation-of-a-next-generation-sequencing-based-t-cell-receptor-gamma-gene-rearrangement-diagnostic-assay-transitioning-from-capillary-electrophoresis-to-next-generation-sequencing/ 2021-04-27T17:17:21+00:00 https://invivoscribe.com/invivoscribe-announces-key-submission-in-the-eu-expanded-presence-and-activity-in-china/ 2021-07-22T17:27:56+00:00 https://invivoscribe.com/the-european-commission-approves-astellas-xospata-for-patients-with-relapsed-or-refractory-acute-myeloid-leukemia-with-a-flt3-mutation-detected-by-validated-tests-including-the-invivos/ 2021-11-14T22:08:08+00:00 https://invivoscribe.com/plan-for-a-successful-international-drug-approval-with-early-development-of-the-accompanying-cdx/ 2022-01-04T04:43:02+00:00 https://invivoscribe.com/ig-gene-clonality-analysis-using-next-generation-sequencing-for-improved-minimal-residual-disease-detection-with-significant-prognostic-value-in-multiple-myeloma-patients/ 2022-01-06T05:38:03+00:00 https://invivoscribe.com/ngs-analysis-of-clonality-and-minimal-residual-disease-in-a-patient-with-concurrent-richters-transformation-and-cll-sll/ 2022-01-08T23:37:03+00:00 https://invivoscribe.com/machine-learning-algorithms-accelerate-throughput-of-a-flow-sequencing-cell-based-assay-for-an-acute-myeloid-leukemia-aml-therapeutic-discovery-platform/ 2022-01-30T21:35:17+00:00 https://invivoscribe.com/real-world-data-on-prognostic-value-of-measurable-residual-disease-assessment-by-fragment-analysis-or-next-generation-sequencing-in-multiple-myeloma/ 2022-09-07T22:22:23+00:00 https://invivoscribe.com/immunoglobulin-gene-rearrangement-in-koreans/ 2022-09-07T22:31:04+00:00 https://invivoscribe.com/invivoscribe-files-spma-with-the-fda-for-use-of-the-leukostrat-cdx-flt3-mutation-assay-to-select-patients-with-newly-diagnosed-flt3-itd-positive-aml/ 2022-10-24T14:57:12+00:00 https://invivoscribe.com/lymphotrack-is-equally-sensitive-as-pcr-genescan-and-sanger-sequencing-for-detection-of-clonal-rearrangements-in-all-patients/ 2022-12-29T21:19:31+00:00 https://invivoscribe.com/comparing-data-generated-using-multiparametric-flow-cytometry-capillary-electrophoresis-and-next-generation-sequencing-in-a-cohort-of-b-cell-lymphoproliferative-disorder-samples/ 2022-12-29T21:22:21+00:00 https://invivoscribe.com/immunoglobulin-heavy-chain-high-throughput-sequencing-in-pediatric-b-precursor-acute-lymphoblastic-leukemia-is-the-clonality-of-the-disease-at-diagnosis-related-to-its-prognosis/ 2023-01-08T18:20:36+00:00 https://invivoscribe.com/feasibility-of-cell-free-dna-collection-and-clonal-immunoglobulin-sequencing-in-south-african-patients-with-hiv-associated-lymphoma/ 2023-01-10T16:48:18+00:00 https://invivoscribe.com/invivoscribe-appoints-masato-sasaki-as-general-manager-of-labpmm-gk-japan/ 2023-02-01T21:02:16+00:00 https://invivoscribe.com/invivoscribe-diagnostic-technologies-shanghai-co-ltd-receives-cap-accreditation-to-support-clinical-research-testing-for-pharmaceutical-partners-in-china/ 2023-02-23T14:28:40+00:00 https://invivoscribe.com/wp-content/uploads/2023/02/IMG_4032-2.jpg https://invivoscribe.com/clonal-characterization-and-somatic-hypermutation-assessment-by-next-generation-sequencing-in-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/ 2023-04-11T03:22:16+00:00 https://invivoscribe.com/minimal-measurable-residual-disease-mrd-monitoring-in-patients-with-lymphoid-neoplasms-by-high-throughput-sequencing-of-the-t-cell-receptor/ 2023-04-11T03:24:04+00:00 https://invivoscribe.com/invivoscribe-announces-ivdr-approval-of-the-leukostrat-cdx-flt3-mutation-assay/ 2023-05-11T10:12:47+00:00 https://invivoscribe.com/wp-content/uploads/2023/05/Screenshot-2023-05-11-at-3.11.31-AM.png https://invivoscribe.com/leveraging-standardized-mrd-assays-to-guide-cll-treatment/ 2024-01-25T18:44:11+00:00 https://invivoscribe.com/quantification-of-measurable-residual-disease-detection-by-next-generation-sequencing-based-clonality-testing-in-b-cell-and-plasma-cell-neoplasms/ 2024-03-03T19:41:21+00:00 https://invivoscribe.com/next-generation-flow-cytometry-for-mrd-detection-in-chinese-patients-with-multiple-myeloma/ 2024-03-26T20:50:51+00:00 https://invivoscribe.com/assessment-of-bone-marrow-involvement-in-b-cell-non-hodgkin-lymphoma/ 2024-03-26T20:55:01+00:00 https://invivoscribe.com/measurable-residual-flt3-internal-tandem-duplication-before-allogeneic-transplant-for-acute-myeloid-leukemia/ 2024-05-02T18:47:00+00:00 https://invivoscribe.com/dna-sequencing-to-detect-residual-disease-in-adults-with-acute-myeloid-leukemia-prior-to-hematopoietic-cell-transplant/ 2024-08-02T21:22:45+00:00 https://invivoscribe.com/innovations-in-mrd-detection/ 2024-09-25T16:19:32+00:00 https://invivoscribe.com/implementation-of-ngs-based-clonality-and-mrd-testing-in-a-high-throughput-environment/ 2024-09-25T17:07:41+00:00 https://invivoscribe.com/beyond-systematic-memory-b-cell-archiving-mining-b-cell-receptor-repertoires-for-antigen-specific-clones-and-tumor-cell-precursors/ 2024-09-25T17:14:27+00:00 https://invivoscribe.com/eu-notified-body-bsi-netherlands-and-the-ema-grant-approval-of-the-leukostrat-cdx-flt3-mutation-assay-for-vanflyta-therapy-in-the-eu-and-eea/ 2024-10-08T10:14:44+00:00 https://invivoscribe.com/wp-content/uploads/2021/02/Invivoscribe-Secondary-Page-2021-Background-Image-001.jpg https://invivoscribe.com/leveraging-highly-sensitive-ngs-flt3-itd-and-npm1-mrd-assessments-in-aml/ 2024-12-18T17:49:08+00:00 https://invivoscribe.com/eha-47th-jstct/ 2025-02-28T02:05:22+00:00 https://invivoscribe.com/jsmo-2025/ 2025-02-28T02:05:49+00:00 https://invivoscribe.com/precision-med-tri-con/ 2025-02-28T02:06:21+00:00 https://invivoscribe.com/bio-europe-spring/ 2025-02-28T02:06:41+00:00 https://invivoscribe.com/uscap/ 2025-02-28T02:07:19+00:00 https://invivoscribe.com/15th-world-cb-cdx-summit-europe/ 2025-02-28T02:08:30+00:00 https://invivoscribe.com/amp-middle-east/ 2025-02-28T02:08:52+00:00 https://invivoscribe.com/eha-balkan-day/ 2025-02-28T02:09:38+00:00 https://invivoscribe.com/bsh/ 2025-02-28T02:10:11+00:00 https://invivoscribe.com/jamt/ 2025-02-28T02:10:35+00:00 https://invivoscribe.com/asgct/ 2025-02-28T02:10:50+00:00 https://invivoscribe.com/eha/ 2025-02-28T02:12:54+00:00 https://invivoscribe.com/icml/ 2025-02-28T02:13:50+00:00 https://invivoscribe.com/the-65th-annual-meeting-of-the-japanese-society-of-lymphoma-research-hematopathology/ 2025-02-28T02:36:29+00:00 https://invivoscribe.com/32nd-japanese-society-for-gene-diagnosis-and-therapy/ 2025-02-28T02:36:44+00:00 https://invivoscribe.com/adlm/ 2025-02-28T02:38:21+00:00 https://invivoscribe.com/soho/ 2025-02-28T02:39:10+00:00 https://invivoscribe.com/jca-annual-meeting/ 2025-02-28T02:40:02+00:00 https://invivoscribe.com/jaclas/ 2025-02-28T02:40:14+00:00 https://invivoscribe.com/jsh-annual-meeting/ 2025-02-28T02:40:28+00:00 https://invivoscribe.com/esmo/ 2025-02-28T02:40:39+00:00 https://invivoscribe.com/jspho-annual-meeting/ 2025-02-28T02:41:02+00:00 https://invivoscribe.com/iccs/ 2025-02-28T02:41:50+00:00 https://invivoscribe.com/amp/ 2025-02-28T02:42:00+00:00 https://invivoscribe.com/medica/ 2025-02-28T02:42:10+00:00 https://invivoscribe.com/the-48th-annual-meeting-of-the-molecular-biology-society-of-japan/ 2025-02-28T02:42:17+00:00 https://invivoscribe.com/ash/ 2025-02-28T02:42:26+00:00 https://invivoscribe.com/from-prognostication-to-precision-in-acute-myeloid-leukemia-2/ 2025-05-08T23:47:49+00:00 https://invivoscribe.com/measurable-residual-disease-and-posttransplantation-gilteritinib-maintenance-for-patients-with-flt3-itd-mutated-aml/ 2025-05-09T16:20:30+00:00 https://invivoscribe.com/amp-global-2019-video-series-part-1-of-4/ 2025-06-02T21:12:09+00:00 https://invivoscribe.com/leveraging-highly-sensitive-ngs-assays-for-clonality-shm-and-mrd-assessments/ 2025-06-02T23:15:53+00:00 https://invivoscribe.com/level-up-your-mrd-testing-video/ 2025-06-10T23:49:59+00:00 https://invivoscribe.com/evolving-role-ngs-and-mrd-in-cll/ 2025-06-10T23:52:28+00:00 https://invivoscribe.com/mrd-applications-and-analysis/ 2025-06-10T23:53:44+00:00 https://invivoscribe.com/ngs-assessment-of-shm-in-cll-sll-a-practical-comparison-of-platforms-and-primers/ 2025-06-10T23:55:03+00:00 https://invivoscribe.com/improving-lives-with-precision-diagnostics/ 2025-06-11T15:39:53+00:00 https://invivoscribe.com/multiparameter-approach-to-cll-diagnosis-prognostic-biomarker-assessment-and-mrd-monitoring/ 2025-06-11T15:51:08+00:00 https://invivoscribe.com/lab-secrets-stratification-and-prognoses-of-leukemia-and-multiple-myeloma-using-next-generation-sequencing-ngs/ 2025-06-11T15:52:03+00:00 https://invivoscribe.com/high-throughput-sequencing-of-tcr-gene-rearrangements-as-a-useful-tool-for-identifying-and-tracking-minimal-measurable-residual-disease-mrd-in-lymphoid-malignancies/ 2025-06-11T15:54:09+00:00 https://invivoscribe.com/ngs-based-clinical-assessment-of-b-and-t-cell-clonality-and-mrd-determination/ 2025-06-11T15:55:28+00:00 https://invivoscribe.com/aml-precision-diagnostics-solution-webinar/ 2025-06-11T15:57:05+00:00 https://invivoscribe.com/next-generation-sequencing-of-immunoglobulin-genes-in-lymphoid-malignancies/ 2025-06-11T17:23:03+00:00 https://invivoscribe.com/review-of-guidelines-for-interpreting-somatic-hypermutation-status-in-chronic-lymphocytic-leukemia-in-the-era-of-high-throughput-sequencing/ 2025-06-11T17:24:56+00:00 https://invivoscribe.com/global-standardization-of-flow-cytometry-results-with-ai-systems/ 2025-06-11T17:26:19+00:00 https://invivoscribe.com/explore-the-benefits-considerations-and-utility-of-ngs-b-and-t-cell-clonality/ 2025-06-11T17:27:17+00:00 https://invivoscribe.com/critical-mistakes-to-avoid-when-developing-a-drug-cdx-combination-for-international-registrations/ 2025-06-11T17:28:13+00:00 https://invivoscribe.com/assessment-of-mrd-by-ngs-in-daily-clinical-management-of-multiple-myeloma/ 2025-06-11T17:30:05+00:00 https://invivoscribe.com/new-frontiers-in-hematology-from-cll-tumor-precursor-cells-to-tracking-disease-burden-in-multiple-myeloma/ 2025-06-11T17:39:30+00:00 https://invivoscribe.com/complementary-value-of-mrd-assessments-by-ngs-and-mfc-for-the-study-of-hematologic-malignancies/ 2025-06-11T17:40:13+00:00 https://invivoscribe.com/artificial-intelligence-ai-and-other-data-science-applications-in-molecular-pathology/ 2025-06-11T17:43:19+00:00 https://invivoscribe.com/clinical-utility-of-ngs-in-lymphoid-malignancies-including-minimal-residual-disease-mrd-testing/ 2025-06-11T17:44:14+00:00 https://invivoscribe.com/virtual-eha-next-generation-analysis-in-cll-and-other-malignancies/ 2025-06-11T17:45:34+00:00 https://invivoscribe.com/virtual-eha-clonality-analysis-with-ngs-is-the-new-frontier-in-mrd-detection/ 2025-06-11T17:51:22+00:00 https://invivoscribe.com/virtual-eha-incorporating-ngs-methods-for-routine-clonality-assessment-and-disease-monitoring-of-lymphoid-malignancies/ 2025-06-11T17:52:18+00:00 https://invivoscribe.com/clinical-utility-of-ngs-in-lymphoid-malignancies/ 2025-06-11T17:53:16+00:00 https://invivoscribe.com/amp-2019-video-series-part-3-of-4/ 2025-06-11T17:55:30+00:00 https://invivoscribe.com/amp-2019-video-series-part-4-of-4/ 2025-06-11T17:56:55+00:00 https://invivoscribe.com/amp-2019-video-series-part-2-of-4/ 2025-06-11T17:58:02+00:00 https://invivoscribe.com/amp-2019-video-series-part-1-of-4/ 2025-06-11T18:10:06+00:00 https://invivoscribe.com/invivoscribe-eha-2019-part-3-of-3/ 2025-06-11T18:10:53+00:00 https://invivoscribe.com/invivoscribe-eha-2019-part-2-of-3/ 2025-06-11T18:11:55+00:00 https://invivoscribe.com/invivoscribe-eha-2019-part-1-of-3/ 2025-06-11T18:13:02+00:00 https://invivoscribe.com/invivoscribe-asco-leukostrat-cdx-flt3-mutation-assay/ 2025-06-11T18:14:50+00:00 https://invivoscribe.com/amp-global-2019-video-series-part-4-of-4/ 2025-06-11T18:15:24+00:00 https://invivoscribe.com/amp-global-2019-video-series-part-3-of-4/ 2025-06-11T18:16:05+00:00 https://invivoscribe.com/amp-global-2019-video-series-part-2-of-4/ 2025-06-11T18:16:49+00:00 https://invivoscribe.com/ngs-based-mrd-testing-for-acute-lymphoblastic-leukemia/ 2025-06-11T18:23:53+00:00 https://invivoscribe.com/a-systematic-evidence-based-workflow-for-classifying-kmt2a-fusions-in-aml/ 2025-07-29T22:39:42+00:00 https://invivoscribe.com/invivoscribe-announces-fda-approval-of-the-leukostrat-cdx-flt3-mutation-assay-to-select-patients-with-flt3-itd-positive-aml-for-treatment-with-vanflyta/ 2025-08-26T14:35:25+00:00 https://invivoscribe.com/wp-content/uploads/2023/07/Press-Release-Image-01.jpg https://invivoscribe.com/hitachi-high-tech-and-invivoscribe-partner-to-advance-molecular-diagnostics-and-precision-medicine/ 2025-08-26T15:08:16+00:00 https://invivoscribe.com/invivoscribe-announces-fda-approval-for-distribution-of-the-leukostrat-cdx-flt3-mutation-assay-as-an-ivd-kit-in-the-united-states/ 2025-08-26T15:11:34+00:00 https://invivoscribe.com/invivoscribe-launches-grant-program/ 2025-08-26T15:18:25+00:00 https://invivoscribe.com/performance-comparison-of-illumina-miseq-and-miseq-i100-systems-using-invivoscribes-lymphotrack-assays/ 2025-09-18T23:16:23+00:00 https://invivoscribe.com/performance-comparison-of-invivoscribes-lymphotrack-assays-between-complete-genomics-dnbseq-g99-and-illumina-miseqtm-ngs-platforms/ 2025-09-18T23:19:52+00:00 https://invivoscribe.com/clonality-and-measurable-residual-disease-mrd-testing-on-the-illumina-nextseq-sequencers/ 2025-09-18T23:20:55+00:00 https://invivoscribe.com/clinical-validation-of-the-leukostrat-companion-diagnostic-for-the-selection-of-patients-with-aml-harboring-fms-like-tyrosine-kinase-3-internal-tandem-duplications-for-treatment-with-quizartin/ 2025-10-28T18:29:07+00:00 https://invivoscribe.com/we-are-invivoscribe-company-overview/ 2025-10-30T18:54:03+00:00 https://invivoscribe.com/measurable-residual-mutated-npm1-before-allogeneic-transplant-for-acute-myeloid-leukemia/ 2025-11-24T17:51:38+00:00 https://invivoscribe.com/invivoscribe-receives-approval-in-japan-for-its-leukostrat-cdx-flt3-mutation-assay-to-assess-acute-myeloid-leukemia-aml-patients-eligible-for-treatment-with-xospata-gilteritinib/ 2025-11-26T23:29:44+00:00 https://invivoscribe.com/invivoscribe-submits-leukostrat-cdx-flt3-mutation-assay-both-in-the-us-and-japan-to-support-daiichi-sankyo-submissions-for-quizartinib/ 2025-11-27T15:56:39+00:00 https://invivoscribe.com/invivoscribe-partners-with-complete-genomics-to-develop-and-commercialize-biomarker-tests-for-oncology-and-cancer-research/ 2025-12-20T02:08:11+00:00 https://invivoscribe.com/wp-content/uploads/2023/06/Screenshot-2023-06-01-at-8.03.15-PM.png https://invivoscribe.com/invivoscribe-announces-updated-reimbursement-for-the-leukostrat-cdx-flt3-mutation-assay-to-select-newly-diagnosed-flt3-itd-positive-aml-patients-eligible-for-vanflyta-in-japan/ 2025-12-29T20:29:29+00:00 https://invivoscribe.com/wp-content/uploads/2023/05/Screenshot-2023-05-25-at-2.12.45-PM.png https://invivoscribe.com/development-and-implementation-of-an-automated-and-highly-accurate-reporting-process-for-ngs-based-cloanlity-testing/ 2025-12-30T23:46:07+00:00 https://invivoscribe.com/comparison-of-complete-genomics-dnbseq-g99a-sequencer-and-illumina-miseqtm-using-invivoscribes-flt3-itd-mrd-assay-and-npm1-mrd-assay/ 2026-01-07T21:13:14+00:00 https://invivoscribe.com/mpaicon/ 2026-02-05T00:08:14+00:00 https://invivoscribe.com/aacr/ 2026-02-05T00:10:28+00:00 https://invivoscribe.com/15th-jsh-international-symposium/ 2026-02-05T00:12:47+00:00 https://invivoscribe.com/asco/ 2026-02-05T00:30:16+00:00 https://invivoscribe.com/26th-jslh/ 2026-02-05T00:34:26+00:00 https://invivoscribe.com/cgc/ 2026-02-05T00:35:28+00:00 https://invivoscribe.com/invivoscribe-launches-leukostrat-kmt2a-mrd-assay-to-advance-high-sensitivity-leukemia-testing-in-clinical-trials-and-patient-management-worldwide/ 2026-02-05T22:09:13+00:00 https://invivoscribe.com/wp-content/uploads/2021/02/Invivoscribe-Secondary-Page-2021-Background-Image-001.jpg https://invivoscribe.com/kronos-bio-and-invivoscribe-partner-on-companion-diagnostic/ 2026-03-09T05:24:18+00:00 https://invivoscribe.com/ecp/ 2026-03-09T05:25:43+00:00 https://invivoscribe.com/application-of-cost-effectiveness-analysis-to-demonstrate-the-potential-value-of-companion-diagnostics-in-chronic-myeloid-leukemia/ 2026-03-09T05:26:54+00:00 https://invivoscribe.com/invivoscribe-expands-flow-cytometry-services-to-accelerate-car-t-immunotherapy-development-and-regulatory-readiness-with-the-initiation-of-cero-therapeutics-phase-1-clinical-trial/ 2026-03-10T01:04:28+00:00 https://invivoscribe.com/wp-content/uploads/2021/02/Invivoscribe-Secondary-Page-2021-Background-Image-001.jpg https://invivoscribe.com/a-streamlined-laboratory-workflow-for-controlling-antibody-and-reagent-lots-on-a-12c-flow-cytometry-system/ 2026-03-10T01:06:14+00:00 https://invivoscribe.com/invivoscribe-premieres-12-color-flow-cytometry-capabilities/ 2026-03-10T01:08:11+00:00 https://invivoscribe.com/labpmm-receives-new-york-state-approval-for-the-npm1-mrd-assay-informing-therapy-and-accelerating-targeted-trials/ 2026-03-10T01:40:09+00:00 https://invivoscribe.com/wp-content/uploads/2021/02/Invivoscribe-Secondary-Page-2021-Background-Image-001.jpg https://invivoscribe.com/study-suggests-critical-link-between-residual-flt3-itd-mutations-in-remission-and-post-transplant-outcomes-in-aml/ 2026-03-10T01:43:04+00:00 https://invivoscribe.com/wp-content/uploads/2021/02/Invivoscribe-Secondary-Page-2021-Background-Image-001.jpg https://invivoscribe.com/invivoscribes-labpmm-gains-new-york-state-approval-for-the-flt3-itd-mrd-assay/ 2026-03-10T01:44:44+00:00 https://invivoscribe.com/wp-content/uploads/2021/02/Invivoscribe-Secondary-Page-2021-Background-Image-001.jpg https://invivoscribe.com/invivoscribe-announces-registration-of-the-leukostrat-cdx-flt3-mutation-assay-in-the-united-kingdom-and-switzerland/ 2026-03-10T01:48:48+00:00 https://invivoscribe.com/wp-content/uploads/2021/02/Invivoscribe-Secondary-Page-2021-Background-Image-001.jpg https://invivoscribe.com/roswell-park-comprehensive-cancer-center-licenses-invivoscribes-lymphotrack-software-for-plug-and-play-pipeline-use/ 2026-03-10T01:50:30+00:00 https://invivoscribe.com/invivoscribe-expands-ivdr-portfolio-with-identiclone-dx-igh-assay-certification/ 2026-03-26T06:07:06+00:00 https://invivoscribe.com/wp-content/uploads/2021/02/Invivoscribe-Secondary-Page-2021-Background-Image-001.jpg